Clinical trial
Chemotherapy in Treating Patients With Metastatic Kidney Cancer
NCT00024388 · Theradex, Industry · Unknown status
Key facts
| NCT number | NCT00024388 |
|---|---|
| Title | Chemotherapy in Treating Patients With Metastatic Kidney Cancer |
| Official title | Phase II Open-Label Study of Taxoprexin (DHA-Paclitaxel) Injection by 2-Hour Intravenous Infusion In Patients With Metastatic, Locally Advanced, or Unresectable Renal Cell Carcinoma |
| Lead sponsor | Theradex, Industry |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Kidney Cancer |
| Intervention type | Drug |
| Interventions | DHA-paclitaxel |
| Start date | Apr 1, 2001 |
| First posted | Jan 14, 2004 |
| Last update posted | Jul 24, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: